{
  "pmcid": "12386619",
  "sha256": "674ea65335b76173cd92b37e83a639d16cc65ef047833f208b95514344dbd3d8",
  "timestamp_utc": "2025-11-09T23:35:48.025028+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.130910505836578,
    "reading_ease": 31.436884565499383,
    "word_count": 257
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Obstructive Sleep Apnea in Atrial Fibrillation Patients"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised controlled trial was conducted in cardiology units, enrolling adult AF patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "conducted in cardiology units, enrolling adult AF patients"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to either polysomnography (PSG) or home sleep apnea testing (HSAT)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was OSA prevalence, assessed over a 12-month period"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the PSG group and 100 to the HSAT group, between January 2020 and June 2021"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 participants in the PSG group and 97 in the HSAT group, using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "OSA prevalence was 65% in the PSG group and 60% in the HSAT group (mean difference = 5%, 95% CI -5% to 15%; p = 0.30)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported in either group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Heart Institute"
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}